Issue No. 38

Pediatric Treatment Guidelines Updated

The "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" has been updated. The new version includes:

• Information about the recently approved protease inhibitor tipranavir and information about new formulations of emtricitabine and lopinavir/ritonavir
• A fully revised and updated Supplement I: Characteristics of Available Antiretroviral Drugs
• Updated information on hepatotoxicity in Supplement III: Adverse Drug Effects
• A Pediatric Antiretroviral Guidelines Working Group Conflict of Interest Disclosure (Appendix B).

All new information in the main document, Appendix A, and Supplement III is highlighted; Appendix B is new and Supplement I has been entirely rewritten, so these sections are highlighted in title only.

The updated guidelines documents are available in the PEDIATRIC GUIDELINES section of the GUIDELINES page on the AIDSinfo Web site (http://aidsinfo.nih.gov/guidelines/).

You can download the guidelines or can request to receive them by e-mail or hard copy on the AIDSinfo Web site.

Your feedback is important!

The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children would like to hear your feedback for this latest revision of the "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection."

Please send your comments with the subject line “Pediatric Comments” to AIDSinfoWebmaster@aidsinfo.nih.gov by November 17, 2005.

ClinicalTrials.gov Info